Market Cap | 4.07M | P/E | - | EPS this Y | 105.60% | Ern Qtrly Grth | - |
Income | 2.67M | Forward P/E | -0.30 | EPS next Y | -265.20% | 50D Avg Chg | -37.00% |
Sales | 16.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -83.00% |
Dividend | N/A | Price/Book | 0.11 | EPS next 5Y | - | 52W High Chg | -95.00% |
Recommedations | 1.70 | Quick Ratio | 19.02 | Shares Outstanding | 2.97M | 52W Low Chg | - |
Insider Own | 2.31% | ROA | 12.96% | Shares Float | 1.36M | Beta | -0.28 |
Inst Own | 48.34% | ROE | 13.69% | Shares Shorted/Prior | 5.24K/9.17K | Price | 0.56 |
Gross Margin | 71.31% | Profit Margin | 19.98% | Avg. Volume | 270,170 | Target Price | 30.33 |
Oper. Margin | -12,123.26% | Earnings Date | Nov 7 | Volume | 93,777 | Change | -5.08% |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
HC Wainwright & Co. | Buy | Aug 22, 24 |
HC Wainwright & Co. | Buy | Jul 23, 24 |
HC Wainwright & Co. | Buy | May 20, 24 |
HC Wainwright & Co. | Buy | Mar 27, 24 |
HC Wainwright & Co. | Buy | Feb 9, 24 |
HC Wainwright & Co. | Buy | Nov 13, 23 |
HC Wainwright & Co. | Buy | Nov 6, 23 |
HC Wainwright & Co. | Buy | Aug 24, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |